Cambrex

Cambrex describes itself as a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical services. Its service areas include drug substance, analytical services, peptides and oligonucleotides (tides), drug product, highly potent APIs, and controlled substances. The company states it has more than 40 years of experience and maintains a global presence with 14 locations.

Cambrex states it has more than 40 years of experience and has grown and expanded its global development and manufacturing network by investing in robust technology and quality infrastructure, establishing an exemplary quality and regulatory track record.

A scientist-led CDMO that collaborates with customers from early development to commercialization.

• Drug Substance

  Development and manufacturing support for challenging APIs and complex processes as they scale.

• Analytical Services

  Customized, phase-appropriate analytical programs across the drug lifecycle, including chromatographic, spectroscopic and mass spectrometric solutions.

• Tides

  Manufacturing of peptides and oligonucleotides, offering solid phase synthesis for early development and liquid phase synthesis for scale-up.

• Drug Product

  Support to advance finished dosage forms through early development and prepare for scale-up.

• Highly Potent APIs

  Containment expertise and development support for highly potent molecules.

• Controlled Substances

  Compliant manufacturing and support for programs involving controlled substances.

• 2022-02-08

  Cambrex wins CMO Leading Company Award[5]凯姆布雷克斯荣获CMO领军企业奖prnasia.com

  Reported: 2022-02-08

  Cambrex announced on February 8 that it had won the annual CMO Leading Company Award in the quality and service category.

• Unconfirmed

  Cambrex completes Tallinn manufacturing capability expansion[6]Cambrex完成塔林制造能力扩建prnewswire.com

  Reported: 2021-05-26

  Cambrex announced completion of an investment project at its Tallinn facility, upgrading its kilogram-scale laboratory to manufacture pharmaceutical intermediates under current good manufacturing practice conditions. Preparation for GMP qualification was underway.

1. 1CDMO | Drug Substance, Drug Product & Analytical Services | Cambrexcambrex.com
2. 2About Us | CDMO | Cambrexcambrex.com
3. 3Analytical Services | CDMO | Cambrexcambrex.com
4. 4Recruitment Policy | CDMO | Cambrexcambrex.com
5. 5凯姆布雷克斯荣获CMO领军企业奖prnasia.com
6. 6Cambrex完成塔林制造能力扩建prnewswire.com
7. 7CDMO Cambrex Celebrates 40^th Anniversary While Investing $100+ Million Into Manufacturing Capacitypharmaceuticalonline.com